Bioequivalence Between Two Tablet Formulations Of Doxycycline Carragenate

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this protocol is to study if two different tablet formulations of doxycycline are bioequivalent to each other.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pfizer
• Treatments: Doxycycline

Criteria

Inclusion Criteria:

• Healthy male subjects between the ages of 18 and 55 years.

• Body Mass Index (BMI) of 18 to 30 kg/m2.

Exclusion Criteria:

• Evidence or history of clinically significant abnormality.

• Any condition possibly affecting drug absorption.

• A positive urine drug screen.